SWISSTO12
19.5.2023 14:01:34 CEST | Business Wire | Press release
Inmarsat, a world leader in global, mobile satellite communications, has announced that SWISSto12, one of Europe’s fastest growing aerospace providers, will develop its new eighth-generation of spacecraft. The three I-8 satellites will provide additional network resilience, securing the future of Inmarsat’s global L-band safety services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230519005018/en/
An illustration of SWISSto12's HummingSat in geostationary orbit. Image credit: SWISSto12
SWISSto12, headquartered in Switzerland, will use its HummingSat satellite platform - in conjunction with unique 3D-printing technologies and specialised Radio-Frequency (RF) and payload products - to develop and manufacture the geostationary satellites, which will launch by 2026.
Just 1.5 cubic metres in volume, the I-8’s will use SWISSto12’s innovative new class of spacecraft which has a form factor up to five times smaller than conventional geostationary satellites yet can still deliver critical safety services with certainty.
The three l-8 satellites will continue to provide the extra layer of resilience to complement the existing constellation and Inmarsat’s two I-6 generation satellites, which were launched in December 2021 and February 2023. In March 2023, Inmarsat announced the first, I-6 F1, had successfully completed testing with ground stations in Western Australia and has now started to provide Ka-band services for the fast-growing Asia Pacific region. The company will begin introducing its L-band capacity and transitioning services to the new satellite throughout 2023.
The second, I-6 F2, which launched in February 2023, is expected to enter operational service over Europe, Africa, and much of the Americas in early 2024.
Each I-8 will also extend Inmarsat’s history of launching and operating radionavigation transponders for Governments and international space agencies. These transponders can enable Satellite-Based Augmentation System (SBAS) services around the world, for example for air traffic controllers or coastguards. SBAS systems uses satellite connectivity, land-based infrastructure, and software to enhance standard GPS/Galileo accuracy of 5 to 10 metres to as little as just 10cm.
Such precise tracking could enable pinpoint safety navigation on aircraft, help emergency services reach vessels in distress more quickly, or allow a raft of industrial innovations, like device tracking in agriculture or advanced, automated transport management systems.
The I-8 satellites will continue to secure Inmarsat’s global safety services into the 2040’s. The company was founded in 1979 under the auspices of the United Nations specifically to provide highly reliable safety communications. Today some 1.6 million seafarers and over 200 airlines rely on Inmarsat’s global L-band network to deliver 99.9% availability every day.
The Inmarsat-8 programme forms part of Inmarsat’s fully-funded technology roadmap, which will include five new satellite payloads added by 2025 to further Inmarsat’s high-speed broadband Global Xpress (GX) network with the launch of the software defined satellites GX 7,8, and 9, aimed for 2025, and the polar coverage satellites GX10a and b, which are aimed for the first half of 2024.
Peter Hadinger, Chief Technology Officer, Inmarsat, said “Every single day people around the world depend on Inmarsat services. Our customers have demanding, and often safety critical, missions that rely on our satellite technology for links that can make the difference. The I-8’s will not only underpin our existing capabilities for the future; but enable ever more advanced safety innovations like SBAS that can ultimately help save more lives. We have chosen SWISSto12 because they have the ground-breaking technology that can make it a reality.”
Emile de Rijk, CEO, SWISSto12, said “We are delighted that Inmarsat has selected SWISSto12 as its partner for its landmark l-8 program. It demonstrates that, with HummingSat, we have created a highly-advanced new class of small geostationary spacecraft that delivers world-leading connectivity capabilities at a fraction of the cost. Our proprietary 3D-printing of Radio Frequency payload technology allows us to push the limits of existing capability and service new and existing business cases for geostationary satellite communications. This is an important step in our journey to better connect and protect every corner of the world.”
ENDS
ABOUT INMARSAT
Inmarsat delivers world leading, innovative, advanced and exceptionally reliable global, mobile communications across the world – in the air, at sea and on land - that are enabling a new generation of commercial, government and mission-critical services. Inmarsat is powering the digitalisation of the maritime industry, making operations more efficient and safer than ever before. It is driving a new era of inflight passenger services for aviation, while ensuring that aircraft can fly with maximum efficiency and safety. Furthermore, Inmarsat is enabling the rapid expansion of the Internet of Things (IoT) and enabling the next wave of world-changing technologies that will underpin the connected society and help build a sustainable future. And now Inmarsat is developing the first-of-its-kind, multi-dimensional communications network of the future, ORCHESTRA.
In November 2021, Inmarsat and Viasat announced the planned combination of the two companies, to create a new leader in global communications.
For further information, follow us: Twitter | LinkedIn | Facebook | YouTube | Instagram.
ABOUT SWISSto12
SWISSto12 is a leading manufacturer of advanced satellite payloads and systems, including the HummingSat: a small yet powerful geostationary telecommunications satellite developed in collaboration with the European Space Agency (ESA) through its public-private-partnership program. The first commercial customer of HummingSat was announced in November 2022. The company’s satellites and payloads benefit from unique and patented 3D-printing technologies and associated Radio Frequency (RF) product designs that deliver lightweight, compact, highly performing, and competitive RF functionality. Besides its space portfolio, the company is also active in telecommunications, surveillance and radar applications for the aeronautic industry. SWISSto12 has developed commercially with success in Europe, the USA and Israel and is amongst the fastest growing aerospace companies in Europe. SWISSto12 spun off in 2011 from the Swiss Federal Institute of Technology in Lausanne (EPFL), is privately owned and backed by prominent Swiss and European Investors.
For further information, visit https://swissto12.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005018/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom